Cyprotex extends development partnership

MACCLESFIELD drug development company Cyprotex has extended its partnership with Sygnature Discovery – a Nottingham-based peer.

The AIM listed group said it has committed another two years to its 
“successful” strategic alliance, with both parties expanding their sales and marketing initiative to provide a fully-integrated discovery chemistry service to accelerate their clients’ drug discovery projects into development.

Dr Anthony Baxter, chief executive at Cyprotex said both businesses had expanded over the past two years – since they began working together – and could now offer customers a wider, broader service.

Describing the partnership as a ‘formidable combined offering’ he said:
“Our experience with Sygnature over the past year has led us both to conclude that we can successfully deliver integrated drug discovery services to our customers, and we wish to strengthen this offering in the future.”